Explore
Search ClinicalTrials.gov
Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.
Results for “Merck”
Sponsor: Stanford University
Cardiovascular Diseases · Atherosclerosis · Type 2 Diabetes · Insulin Resistance
United States
- Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.Active Not Recruiting
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Pancreatic Cancer
United States
- Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)Active Not Recruiting
Sponsor: EMD Serono Research & Development Institute, Inc.
Ovarian Cancer
United States, Australia, Belgium, Denmark, France +8 more
Sponsor: University of Pennsylvania
Cytomegalovirus Infections · Transplant-Related Disorder
United States
Sponsor: Merck Sharp & Dohme LLC
HIV-1 Infection
United States, Argentina, Canada, Chile, Colombia +8 more
Sponsor: Luis Montaner
HIV-1-infection
Sponsor: Merck Sharp & Dohme LLC
Healthy
United States
- Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023)Active Not Recruiting
Sponsor: Merck Sharp & Dohme LLC
Papillomavirus Infections
China
- A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)Active Not Recruiting
Sponsor: Dana-Farber Cancer Institute
Endometrial Cancer
United States
Sponsor: Merck Sharp & Dohme LLC
Small Cell Lung Carcinoma
United States, Australia, Austria, Canada, Hungary +7 more
Sponsor: Merck Sharp & Dohme LLC
Metabolic Dysfunction-Associated Steatotic Liver Disease · Non-alcoholic Fatty Liver Disease · Nonalcoholic Fatty Liver Disease · Liver Disease
United States, Puerto Rico
- A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast CancerActive Not Recruiting
Sponsor: Memorial Sloan Kettering Cancer Center
Breast Cancer
United States
Sponsor: American Society of Clinical Oncology
Lymphoma, Non-Hodgkin · Multiple Myeloma · Advanced Solid Tumors
United States, Puerto Rico
Sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Pulmonary Arterial Hypertension
United States, Australia, Belgium, Canada, France +7 more
Sponsor: Daiichi Sankyo
Advanced Solid Tumor · Malignant Solid Tumor
United States, Japan
- Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial CancerActive Not Recruiting
Sponsor: Astellas Pharma Global Development, Inc.
Urothelial Cancer
United States, Argentina, Australia, Belgium, Canada +20 more
- Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1Active Not Recruiting
Sponsor: Gilead Sciences
HIV-1-Infection
United States, Argentina, Australia, Germany, Japan +9 more
- Assessment of Multi-Level Interventions to Improve Adherence to Oral Medications in Cancer PatientsRecruiting
Sponsor: Thomas Jefferson University
Cancer
United States
- A Clinical Study of Enlicitide Decanoate in People With Liver Function Problems (MK-0616-030)Completed
Sponsor: Merck Sharp & Dohme LLC
Hepatic Insufficiency · Hepatic Impairment
United States
- Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)Active Not Recruiting
Sponsor: Eli Lilly and Company
Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Endometrial Neoplasms · Ovarian Neoplasms
United States, Australia, Canada, France, Japan +1 more
- A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)Active Not Recruiting
Sponsor: Daiichi Sankyo
Advanced Solid Tumor · Metastatic Solid Tumors
United States, Belgium, China, Denmark, France +4 more
Sponsor: Merck Sharp & Dohme LLC
Relapsed or Refractory Diffuse Large B-Cell Lymphoma
United States, Canada, Chile, China, Czechia +12 more
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Oligometastatic Squamous Cell Carcinoma of the Head and Neck
Belgium, Italy, Spain, Switzerland
- Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)Active Not Recruiting
Sponsor: EMD Serono Research & Development Institute, Inc.
Metastatic or Locally Advanced Unresectable Solid Tumors
United States, Australia, Canada, South Korea, Spain
- Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)Active Not Recruiting
Sponsor: EMD Serono Research & Development Institute, Inc.
Non-Small Cell Lung Cancer
United States, Belgium, France, Germany, Italy +3 more